Abstracts tagged "Fracture"

Abstract Number: 1727 • ACR Convergence 2025
Distribution of Fracture Risk Status and Osteoporosis Treatment Use Among Postmenopausal Women with Osteoporosis in the United States
Hsu-Chih Chien, Min Kim, Michele McDermott, Mary Oates, Xiaodong Li and Lara Yoon, Amgen Inc, Thousand Oaks, CA
Background/Purpose: Current guidelines recommend treating women with postmenopausal osteoporosis (PMO) based on fracture risk. Anabolic therapy (AT), the RANKL inhibitor denosumab (Dmab), and intravenous zoledronic…
Abstract Number: 1352 • ACR Convergence 2025
Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
Marco Di Paola¹, Edmund J MacLaughlin², Kathleen Methric³, Maurizio Muratore⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Fabiola Rosa Contaldo⁷, Fiorella Anna Lombardi¹, Paola Pisani¹, Francesco Conversano¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³BoneVue Diagnostics, Catonsville, MD, ⁴ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Autoimmune arthritis, including Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PA), are among the most common forms of inflammatory joint diseases. These conditions affect joints…
Abstract Number: 1313 • ACR Convergence 2025
Retrospective Analysis of Factors Associated With Fracture in 2855 Patients With Rheumatoid Arthritis, Stratified by Steroid Use
Jonathan Barnes¹, Hamzah Amin² and marwan Bukhari³, ¹Morecambe Bay NHS Trust, Lancaster, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Steroids are used in a proportion of patients with rheumatoid arthritis (RA). Steroids are known to cause a decrease in bone mineral density (BMD),…
Abstract Number: 0867 • ACR Convergence 2025
NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation
Wen Sun and Hua Wang, Nanjing Medical University, Nanjing, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a frequent comorbidity. The NLRP3 inflammasome, a key mediator of…
Abstract Number: 2685 • ACR Convergence 2025
Assessing for Racial/Ethnic Variability in U.S.-FRAXTM Performance Among Older Adult Women with Rheumatoid Arthritis in the United States
Rachel Elam¹, Jing Li², Angel Paul³, Emma Kersey⁴, gabriela Schmajuk⁵, William Leslie⁶ and Laura Carbone¹, ¹Augusta University, Augusta, GA, ²University of California, San Francisco, San Francisco, CA, ³University of California San Francisco, Berkeley, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁶University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Women with rheumatoid arthritis (RA) have 1.5- and 2-fold higher risk of major osteoporotic fracture (MOF: first of distal forearm, hip, humerus, or clinical…
Abstract Number: 0354 • ACR Convergence 2025
Greater Neighborhood Walkability is Associated with Lower Incidence of Hip Fracture in Older, Community-dwelling Women in the United States: The Cardiovascular Health Study
Rachel Elam¹, Petra Buzkova², Howard Fink³, Joshua Barzilay⁴, Eric Roseen⁵, Jane Cauley⁶, John Robbins⁷, Laura Carbone¹, Gina Lovasi⁸ and Kenneth Mukamal⁹, ¹Augusta University, Augusta, GA, ²University of Washingon, Seattle, WA, ³University of Minnesota, Minneapolis, MN, ⁴Kaiser Permanente of Georgia, Atlanta, GA, ⁵Boston University, Boston, MA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of California Davis, Davis, CA, ⁸Drexel University, Philadelphia, PA, ⁹Beth Israel Deaconess Medical Center, Brookline, MA
Background/Purpose: Higher physical activity is linked to reduced fracture risk in older adults, especially for hip fractures. Emerging evidence demonstrates a potential role for the…
Abstract Number: 2621 • ACR Convergence 2025
Erosive Hand Osteoarthritis Is Associated With Increased Risk of Incident Osteoporotic Fractures In Post-menopausal Women (QUALYOR Cohort)
MAXIME AUROUX¹, MERCIER-GUERY Alexandre¹, PIOT Anne², MERLE Blandine³, PRORIOL Mathilde¹, FONTANGES Elisabeth¹, DUVERT Florence¹, Eric LESPESSAILLES⁴ and CHAPURLAT Roland¹, ¹Hospices Civils de Lyon, LYON, France, ²Centre Hospitalier Lucien Hussel, VIENNE, France, ³INSERM U¹⁰³³, LYON, France, ⁴University Hospital of Orléans, Orleans, France
Background/Purpose: Erosive hand osteoarthritis (ErHOA) is a severe form of hand osteoarthritis (HOA) characterized by greater inflammation and higher burden of disease. In this more…
Abstract Number: 0352 • ACR Convergence 2025
Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures
Marshall Weber¹, William Obremskey², Jared Huling³, Nitya Shah³, Emily Budde⁴, Zhiping Huo⁴, Reside Jacob⁴, Brinda Basida¹, Colton Hoffer¹, Binni Makkar⁵ and Laura Carbone¹, ¹Augusta University, Augusta, GA, ²Vanderbilt University, Nashville, TN, ³University of Minnesota School of Public Health, Minneapolis, MN, ⁴Center of Innovation for Complex Chronic Healthcare, Washington DC, DC, ⁵University of Kentucky, Lexington, KY
Background/Purpose: Atypical femoral fractures (AFFs) are a rare complication of bisphosphonate use and a major reason that drug holidays are recommended following bisphosphonate use. However,…
Abstract Number: 2479 • ACR Convergence 2025
REMS technology 5-y Imminent Fracture Risk in Systemic Sclerosis.
Fiorella Anna Lombardi¹, Edmund J MacLaughlin², Marco Di Paola¹, Maurizio Muratore³, Kathleen Methric⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Andrea Claudio Ştețco⁷, Francesco Conversano¹, Paola Pisani¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁴BoneVue Diagnostics, Catonsville, MD, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Systemic sclerosis (SS) is a rare connective tissue disorder characterized by progressive fibrosis of the skin and internal organs, including lungs, heart and kidneys.…
Abstract Number: 0353 • ACR Convergence 2025
Incidence of Clinical Fragility Fractures and Mortality in Patients with Rheumatoid Arthritis Treated with Rituximab
Montserrat Roig Kim¹, Carla Marco-Pascual², Martí Aguilar-Coll¹, Javier Narváez³, Joan Miquel Nolla¹ and Carmen Gomez Vaquero⁴, ¹Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, ⁰⁸⁹⁰⁷ L'Hospitalet, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have an increased risk of osteoporosis and fragility fractures. Bone loss in RA is multifactorial and mainly determined by…
Abstract Number: 2113 • ACR Convergence 2025
Mortality rate in patients with hip fracture: is it recommendable to establish fracture units?
Esther Monleon Acosta¹, Alicia Pérez González², José Andrés Rodríguez Fernández², Pedro José Manuel Hernández², María del Rosario Oliva Ruiz², José María Andreu Ubero², Paloma Valentina Castillo Dayer², Gloria Albaladejo Paredes³, Carlos Fernández Díaz⁴, Angela Egea Fuentes², Montserrat Fernández Salamanca² and Vicente Cogolludo Campillo⁵, ¹Hospital Santa Lucia, Cartagena, Spain, ²Hospital General Universitario Santa Lucia, Cartagena, Spain, ³Hospital General Universitario Santa Lucía, CARTAGENA, Spain, ⁴H.U. Santa Lucia, Murcia, Spain, ⁵Hospital General Universitario Santa Lucia, Santa Lucia, Cartage, Spain
Background/Purpose: Hip fracture is the second most common osteoporotic fracture and the one with the highest socio-economic cost. It is associated with high morbidity and…
Abstract Number: 0351 • ACR Convergence 2025
Experience with romosozumab in women with osteoporosis at high risk of fracture in real-world clinical practice
MARIA DEL CARMEN ORTEGA DE LA O¹, Laura Gonzalez Hombrado², Marina Salido Olivares³, Carolina Marin⁴, Angel Aragon⁵, Celia arconada⁶, Maria Carmen Ortega de la O⁷, Alvaro Garcia⁸, elisabeth Castañeda⁹, Patricia Castro Perez¹⁰, alberto diaz Oca¹¹ and Eva Andres Esteban¹², ¹HOSPITAL UNIVERSITARIO GETAFE, GETAFE, Madrid, Spain, ²Hospital Universitario del Tajo, Aranjuez (MADRID), Madrid, Spain, ³Hospital Clinico San Carlos, Madrid, Madrid, Spain, ⁴Hospital Infanta Leonor, Madrid, Madrid, Spain, ⁵Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain, ⁶Hospital universitario de Getafe, Getafe, Madrid, Spain, ⁷Hospital Universitario Getafe, Madrid, Madrid, Spain, ⁸Hospital Universitario del Tajo, Aranjuez, Madrid, Spain, ⁹Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ¹⁰Hospital de Getafe, Madrid, Madrid, Spain, ¹¹Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain, ¹²Universidad Rey Juan Carlos, Fuenlabrada, Spain
Background/Purpose: Romosozumab (RMZ) is a recently approved dual-acting drug which has been shown to reduce fracture risk in patients with osteoporosis (OP) in clinical trials.…
Abstract Number: 2122 • ACR Convergence 2025
Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
Maryia Nikitsina¹, Cristina Valero², Miren Uriarte Ecenarro³, Ana M Ortiz³, María Ahijón Lana³, Irene Llorente³, Marina Dueñas-Ochoa⁴, Juan C Saez⁵, EVA GLORIA TOMERO MURIEL⁶, Esther Vicente-Rabaneda⁶, Isidoro Gonzalez-Alvaro⁷, Rosario Garcia Vicuña⁶ and Santos Castañeda⁸, ¹University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Hospital Universitario La Princesa, Madrid, Spain, ⁴Hospital La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Romosozumab (RSZ) is a dual osteoanabolic agent that stimulates bone formation and reduces bone resorption, emerging as a promising option for treating osteoporosis (OP)…
Abstract Number: 0347 • ACR Convergence 2025
Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Kabyar Cho¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Coeliac disease (CD) is an autoimmune disease, which has been widely reported to be associated with reduced bone mineral density (BMD), leading to an…
Abstract Number: 2119 • ACR Convergence 2025
Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity
Winnie Liu¹, Jeffrey Curtis², Lars Folkestad³, Emily Holladay⁴, Jingyi zhang², Shanette Daigle⁵, Ye Liu², Fenglong Xie⁶ and Eric Orwoll¹, ¹Oregon Health and Science University, Portland, OR, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Southern Denmark, Odense, Denmark, Odense, Denmark, ⁴Foundation for Advancing Science Technology Education and Research, Hoover, AL, ⁵Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁶The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility caused by mutations related to type 1 collagen biosynthesis. Fractures are a…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].